• Orexo announced November 13, 2026, that new OX640 data had been presented at the ACAAI annual meeting.
• The investigational nasal epinephrine powder reached clinically meaningful levels fastest under allergic rhinitis conditions, compared with normal conditions or intramuscular epinephrine.
• OX640 retained greater potency than an epinephrine autoinjector or liquid nasal spray following one year under accelerated aging conditions.
• The treatment remains in clinical development as a needle-free alternative to epinephrine autoinjectors for severe allergic reactions, including anaphylaxis.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Orexo AB published the original content used to generate this news brief on November 13, 2026, and is solely responsible for the information contained therein.